Bessemer Group’s Unity Biotechnology UBX Stock Holding History

Bessemer Group’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,530	Closed	-$914K	–	1663
2020 Q2	$914K	Buy	+10,530	New	+$781K	﹤0.01%	826

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bessemer Group's UBX Position: Q3 2020 in Review

Bessemer Group sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 10,530 shares — an estimated $914K sold.

Bessemer Group first reported a position in UBX in Q2 2020 and held it in 1 quarter. The position peaked at $914K in Q2 2020. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

Bessemer Group reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
Bessemer Group sold 10,530 Unity Biotechnology shares in Q3 2020, an estimated $914K.
Bessemer Group first reported a position in Unity Biotechnology in Q2 2020 and held it in 1 quarter.
Bessemer Group's Unity Biotechnology position peaked at $914K in Q2 2020.
79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.